ReviewBritish journal of haematology2015
Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?
Review in British journal of haematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 178 citations in OpenAlex.
- Prognostic factors of Erdheim-Chester disease: a nationwide survey in Japan.Haematologica · 2018Trial
- Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.International journal of hematology · 2018Trial
- Histiocytosis development and clinical variation through the lens of genomics.The Journal of pathology · 2026Review
- Prognostic factor analysis of oral and maxillofacial Langerhans cell histiocytosis based on clinical findings and tumour microenvironment.BMC oral health · 2026Article
- Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment.Hematology. American Society of Hematology. Education Program · 2025Review
- Luvometinib in patients with Langerhans cell histiocytosis, Erdheim-Chester disease, and other histiocytic neoplasms: a single-arm, multicentre, phase 2 study.EClinicalMedicine · 2025Article
- Skull base Langerhans cell histiocytosis presenting as persistent ear discharge with granulation-like tissue in the external ear canal.BMJ case reports · 2025Article
- Differential Gene Analysis of Langerhans Cell Histiocytosis and the Significance of MMP1-Targeted Drug Repositioning.Molecular biotechnology · 2025Article
- Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature.Cancer reports (Hoboken, N.J.) · 2024Review
- Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures.Cancer · 2024Review
- Orbital histiocytosis; From A to Z.International ophthalmology · 2024Review
- Exploration of treatment in childhood Langerhans cell histiocytosis based on inflammatory and malignant symptoms: a pilot study.Orphanet journal of rare diseases · 2024Article
- Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders.Haematologica · 2024Article
- Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling.Clinical and experimental medicine · 2023Article
- Novel therapeutic approaches for pediatric diencephalic tumors: improving functional outcomes.Frontiers in oncology · 2023Review
- Langerhans Cell Histiocytosis of the Uvea with a Ciliochoroidal Mass: A Case Report of Management with Systemic Therapy.Case reports in ophthalmological medicine · 2023Article
- Cholesteatoma Masquerading as Recurrent Langerhans Cell Histiocytosis.The journal of international advanced otology · 2023Article
- BRAF-V600E utilizes posttranscriptional mechanisms to amplify LPS-induced TNFα production in dendritic cells in a mouse model of Langerhans cell histiocytosis.Journal of leukocyte biology · 2022Article
- Development of BRAFV600E-positive acute myeloid leukemia in a patient on long-term dabrafenib for multisystem LCH.Blood advances · 2022Article
- [Red-brown, erosive papules in an infant].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2022Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Langerhans cell histiocytosis (LCH), the most common histiocytic disorder, is characterized by the accumulation of CD1A(+) /CD207(+) mononuclear phagocytes within granulomatous lesions that can affect nearly all organ systems. Historically, LCH has been presumed to arise from transformed or pathologically activated epidermal dendritic cells called Langerhans cells. However, new evidence supports a model in which LCH occurs as a consequence of a misguided differentiation programme of myeloid dendritic cell precursors. Genetic, molecular and functional data implicate activation of the ERK signalling pathway at critical stages in myeloid differentiation as an essential and universal driver of LCH pathology. Based on these findings, we propose that LCH should be re-defined as an inflammatory myeloid neoplasia. Increased understanding of LCH pathogenesis will provide opportunities to optimize and personalize therapy through improved risk-stratification, targeted therapy and assessment of therapy response based on specific molecular features and origin of the pathological myeloid cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.